PT - JOURNAL ARTICLE AU - Vassallo, Ralph R. AU - Bravo, Marjorie D. AU - Dumont, Larry J. AU - Hazegh, Kelsey AU - Kamel, Hany TI - Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors AID - 10.1101/2020.09.17.20195131 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.17.20195131 4099 - http://medrxiv.org/content/early/2020/09/18/2020.09.17.20195131.short 4100 - http://medrxiv.org/content/early/2020/09/18/2020.09.17.20195131.full AB - Background To identify blood donors eligible to donate Coronavirus Disease-2019 (COVID-19) Convalescent Plasma (CCP), a large blood center began testing for antibodies to SARS-CoV-2, the etiologic agent of COVID-19. We report the seroprevalence of total immunoglobulin directed against the S1 spike protein of SARS-CoV-2 in US blood donors.Methods Unique non-CCP donor sera from June 1–July 31, 2020 were tested with the Ortho VITROS Anti-SARS-CoV-2 total immunoglobulin assay (positive: signal-to-cutoff (S/C) ≥1). Donor age, sex, race/ethnicity, ABO/RhD, education, and experience were compared to June and July 2019. Multivariate regressions were conducted to identify demographics associated with the presence of antibodies and with S/C values.Results Unique donors (n=252,882) showed an overall seroprevalence of 1.83% in June (1.37%) and July (2.26%), with the highest prevalence in northern New Jersey (7.3%). In a subset of donors with demographic information (n=189,565), higher odds of antibody reactivity were associated with non-Hispanic Native American/Alaskan (NH-NAA/A) and Black (NH-B), and Hispanic (H) race/ethnicity, age 18-64, middle school or lesser education, blood Group A, and never or non-recent donor status. In positive donors (n=2,831), antibody signal was associated with male sex, race/ethnicity (NH-NAA/A, NH-B and H) and geographic location.Conclusions Seroprevalence remains low in US blood donors but varies significantly by region. Temporal trends in reactivity may be used to gauge the effectiveness of public health measures. Before generalizing these data from healthy donors to the general population however, rates must be corrected for false positive test results among low prevalence test subjects and adjusted to match the wider demography.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport for SARS-CoV-2 Antibody testing was provided by Vitalant and its contributors: Blood Center Foundation of the Inland Northwest, Blood Science Foundation, Bonfils Blood Center Foundation Donor-Advised Fund. Additional funding for data-sharing was provided under CDC Contract 75D301-20-C-08170.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advarra has certified this research effort exempt (Protocol 00030878).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the paper are contained within its tables and figures.